Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Lawrence Loomis is active.

Publication


Featured researches published by Lawrence Loomis.


Proceedings of the National Academy of Sciences of the United States of America | 2001

Prevention and elimination of upper respiratory colonization of mice by group A streptococci by using a bacteriophage lytic enzyme

Daniel C. Nelson; Lawrence Loomis; Vincent A. Fischetti

Bacteriophage lytic enzymes quickly destroy the cell wall of the host bacterium to release progeny phage. Because such lytic enzymes specifically kill the species in which they were produced, they may represent an effective way to control pathogenic bacteria without disturbing normal microflora. In this report, we studied a murein hydrolase from the streptococcal bacteriophage C1 termed lysin. This enzyme is specific for groups A, C, and E streptococci, with little or no activity toward several oral streptococci or other commensal organisms tested. Using purified lysin in vitro, we show that 1,000 units (10 ng) of enzyme is sufficient to sterilize a culture of ≈107 group A streptococci within 5 seconds. When a single dose of lysin (250 units) is first added to the oral cavity of mice, followed by 107 live group A streptococci, it provides protection from colonization (28.5% infected, n = 21) compared with controls without lysin (70.5% infected, n = 17) (P < 0.03). Furthermore, when lysin (500 units) was given orally to 9 heavily colonized mice, no detectable streptococci were observed 2 h after lysin treatment. In all, these studies show that lysin represents a unique murein hydrolase that has a rapid lethal effect both in vitro and in vivo on group A streptococci, without affecting other indigenous microorganisms analyzed. This general approach may be used to either eliminate or reduce streptococci from the upper respiratory mucosal epithelium of either carriers or infected individuals, thus reducing associated disease.


Archive | 2000

Use of bacterial phage associated lysing enzymers for the prophylactic and therapeutic treatment of various illnesses

Vincent A. Fischetti; Lawrence Loomis


Archive | 2000

Topical treatment of streptococcal infections

Vincent A. Fischetti; Lawrence Loomis


Archive | 2000

Bacterial phage associated lysing enzymes for treating dermatological infections

Vincent A. Fischetti; Lawrence Loomis


Archive | 1999

Therapeutic treatment of group A streptococcal infections

Vincent A. Fischetti; Lawrence Loomis


Archive | 2002

Use of bacterial phage associated lysing enzymes for treating various illnesses

Lawrence Loomis; Vincent A. Fischetti


Archive | 2001

Parenteral use of bacterial phage associated lysing enzymes for the therapeutic treatment of bacterial infections

Vincent A. Fischetti; Lawrence Loomis


Archive | 2002

Use of phage associated lytic enzymes for treating bacterial infections of the digestive tract

Vincent A. Fischetti; Lawrence Loomis


Archive | 2000

Composition incorporating bacterial phage associated lysing enzymes for treating dermatological infections

Vincent A. Fischetti; Lawrence Loomis


Archive | 2000

Use of bacterial phage associated lysing enzymes for treating bacterial infections of the mouth and teeth

Vincent A. Fischetti; Lawrence Loomis

Collaboration


Dive into the Lawrence Loomis's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Raymond Schuch

Uniformed Services University of the Health Sciences

View shared research outputs
Researchain Logo
Decentralizing Knowledge